Barclays PLC Lowers Stock Position in Allakos Inc. (NASDAQ:ALLK)

Barclays PLC trimmed its stake in Allakos Inc. (NASDAQ:ALLK) by 23.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 869,969 shares of the company’s stock after selling 264,049 shares during the period. Barclays PLC owned about 0.97% of Allakos worth $568,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ALLK. FMR LLC increased its holdings in Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after purchasing an additional 685,623 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Allakos by 32.4% in the second quarter. Acadian Asset Management LLC now owns 1,762,814 shares of the company’s stock valued at $1,761,000 after buying an additional 431,175 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Allakos in the 3rd quarter valued at $1,143,000. GSA Capital Partners LLP lifted its stake in Allakos by 11.9% during the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after acquiring an additional 84,750 shares in the last quarter. Finally, RBF Capital LLC lifted its stake in Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after acquiring an additional 160,529 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Allakos Stock Up 1.7 %

NASDAQ:ALLK opened at $1.21 on Thursday. Allakos Inc. has a 52 week low of $0.54 and a 52 week high of $3.36. The company has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $0.91. The company has a market cap of $108.11 million, a price-to-earnings ratio of -0.60 and a beta of 0.92.

Allakos (NASDAQ:ALLK) last released its earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, analysts expect that Allakos Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $3.00 target price on shares of Allakos in a research report on Thursday, September 26th.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.